Subjective cognitive symptoms improve following effective migraine treatment: A patient‐reported outcome study
- 28 October 2026
- journal article
- Published by Wiley in Headache: The Journal of Head and Face Pain
Abstract
Objectives/Background: Our objective was to investigate whether subjective cognitive symptoms improve after effective preventive migraine treatment. Subjective cognitive symptoms, such as memory and concentration difficulties, are increasingly recognized as part of the clinical spectrum of migraine. We aimed to evaluate whether subjective cognitive symptoms improve with effective preventive migraine treatment acting predominantly outside the central nervous system. Methods: We conducted a prospective two‐center observational cohort study with a pre–post (within‐person) design including adults with migraine diagnosed according to the International Classification of Headache Disorders, 3rd edition criteria, who initiated preventive treatment with either anti‐calcitonin gene‐related peptide/calcitonin gene‐related peptide receptor monoclonal antibodies or onabotulinumtoxinA at two tertiary headache centers in Portugal between October 2023 and August 2025. Treatment response was defined as a ≥50% reduction in monthly moderate to severe headache days in patients with episodic migraine and a ≥30% reduction in those with chronic migraine, assessed between baseline and 3–6 months of follow‐up. Subjective cognitive symptoms, assessed using the Subjective Memory Complaints scale, and depression and anxiety symptoms, evaluated with the Hospital Anxiety and Depression Scale, were compared between baseline and follow‐up according to treatment responder status. Results: Participants ( N = 96, mean age 42.4±12.0 years, 94/96 [98%] women, 68/96 [71%] with chronic migraine), received either anti‐calcitonin gene‐related peptide/receptor monoclonal antibodies ( n = 65) or onabotulinumtoxinA ( n = 31), and 51 responded to treatment. Treatment responders showed greater improvement in subjective cognitive symptoms than nonresponders ( B = −2.22, 95% CI = −3.62 to −0.82, p = 0.002), regardless of preventive treatment type ( B = 0.17, 95% CI = −1.34 to 1.68, p = 0.825) and baseline depression ( B = 0.02, 95% CI = −0.21 to 0.24, p = 0.894) and anxiety ( B = −0.06, 95% CI = −0.25 to 0.13, p = 0.545) symptoms. Although in patients with borderline or clinically significant depression symptoms, cognitive improvement was primarily associated with improvement in depression symptoms ( B = 0.35, 95% CI = 0.03–0.68, p = 0.033; B = 0.61, 95% CI = 0.32–0.90, p < 0.001; respectively), among patients without baseline depression symptoms, cognitive improvement was only associated with treatment response ( B = −1.77, 95% CI = −3.32 to −0.21, p = 0.027). Conclusion: This study shows that effective preventive treatment is associated with significant improvement in subjective cognitive symptoms, highlighting their responsiveness to treatment and relevance to patient‐reported outcomes. imageKeywords
This publication has 32 references indexed in Scilit:
- Anti-CGRP monoclonal antibodies, migraine and mood disorders: an observational study.Neurological Sciences, 2025
- Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressive DisorderJAMA Neurology, 2025
- In search of a neuropsychological profile for migraine: A scoping reviewEuropean journal of pain, 2024
- Depression and treatment with anti‐calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies for migraineEuropean Journal of Neurology, 2023
- The effect of erenumab on brain network function in episodic migraine patients: a randomized, placebo-controlled clinical trial (RESET BRAIN)Journal of Neurology, 2023
- Patient‐reported experiences with migraine‐related cognitive symptoms: Results of the MiCOAS qualitative studyHeadache: The Journal of Head and Face Pain, 2023
- Interictal Cognitive Deficits in Migraine Sufferers: A Meta-AnalysisNeuropsychology Review, 2021
- Migraine as a Cortical Brain DisorderHeadache: The Journal of Head and Face Pain, 2020
- Life With Migraine: Effects on Relationships, Career, and Finances From the Chronic Migraine Epidemiology and Outcomes (CaMEO) StudyHeadache: The Journal of Head and Face Pain, 2019
- Memory complaints in healthy young and elderly adults: Reliability of memory reportingAging & Mental Health, 2008